Developer docs
API playgroundTry for free, no card

Search company profiles

Hera Biotech

Full company profile

uuid0000f93

Namestring
Hera Biotech
Legal namestring
Hera Biotech, Inc.
Websiteurl
herabiotech.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Hera Biotech is a clinical-stage biotechnology company developing non-invasive, tissue-based diagnostics for two under-served areas of women's health: endometriosis and cervical cancer. Its core products are MetriDx, a laboratory-developed molecular test that uses RT-qPCR mRNA expression profiling augmented by AI/ML algorithms to detect and stage endometriosis (reported at 80% sensitivity and 95% specificity), and HERAfem, a point-of-care cervical cancer diagnostic device that combines optical and electrical spectroscopy with on-device AI to detect CIN1+ lesions (reported at 90% sensitivity and 77% specificity). Both products run on a shared adaptive AI platform that improves with each diagnostic result and is trained on 20 billion+ data points across 1,000+ samples and four proprietary datasets.

The company targets OB-GYN clinics, fertility clinics, primary care settings, reference laboratories, and public health systems. Its revenue strategy is multi-modal: MetriDx operates under a Laboratory Developed Test (LDT) model with unique billing opportunities and potential of up to $4M annual revenue per average fertility clinic; HERAfem is positioned as a hardware device sale targeting Latin America (2026), Asia, and Africa (2027). The company is also pursuing reimbursement pathways that could reduce endometriosis diagnostic cost by approximately $17K per patient. Both products remain under development and have not yet received FDA or COFEPRIS approval.

Hera Biotech is a Delaware corporation headquartered in San Antonio, Texas, with regional operations in Monterrey, Mexico and Basel, Switzerland. It is led by CEO Somer Baburek (2 prior exits) and COO/CSO Cinzia Donato, PhD (multi-patent holder, formerly at Scailyte), and is venture-backed with approximately $2M in seed funding plus a $100K Cedars-Sinai Accelerator grant, while actively raising a Series A round for commercialization.

Short descriptiontext

Hera Biotech is a clinical-stage women's health biotech developing AI-powered, non-invasive diagnostics for endometriosis (MetriDx) and cervical cancer (HERAfem), targeting OB-GYN, fertility clinics, primary care, and public health systems across the US, Latin America, Asia, and Africa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive diagnostics, molecular diagnostic testing, AI-powered diagnostics, women's health devices, cervical cancer screening
Industry2 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Women's Health Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1MetriDx™ Diagnostic Testing
TypeOne Time License
Description

Lab-developed test (LDT) model for endometriosis detection, generating revenue through laboratory testing fees prior to FDA approval. Proprietary components and workflow enable unique billing opportunities. Estimated potential of up to $4M annual revenue per average fertility clinic.

herabiotech.com
2HERAfem™ Device Sales
TypeHardware Sales
Description

Point-of-care diagnostic device for cervical cancer screening. Revenue streams planned to turn on pre-COFEPRIS clearance in Latin America (2026) with expansion to Asia and Africa (2027). Device designed for wireless operation with data backup capabilities.

herabiotech.com
3Reimbursement and Billing
TypeTransaction Fee
Description

Proprietary diagnostic workflow with unique billing opportunities. MetriDx can cut diagnostic cost by approximately $17K per patient compared to traditional surgical pathway, with reimbursement pathways already in motion.

herabiotech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MetriDx™
Description

Non-invasive molecular test for endometriosis detection and staging using mRNA expression profiling via RT-qPCR with AI-powered algorithms. 80% sensitivity, 95% specificity. Targets to replace surgical diagnostic laparoscopy.

herabiotech.com
+1 more record
Core offering1 text field

Hera Biotech develops non-invasive, tissue-based AI-powered diagnostic products for women's health. Its core offerings are MetriDx™, a molecular test using mRNA expression profiling (RT-qPCR) for endometriosis detection and staging (80% sensitivity, 95% specificity), and HERAfem™, a point-of-care cervical cancer diagnostic device using optical and electrical spectroscopy (90% sensitivity, 77% specificity). Both products are powered by a shared adaptive AI/ML platform trained on over 20 billion data points.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • MetriDx achieves 80% sensitivity and 95% specificity for endometriosis detection
+5 more records
Product overview1 text field

Hera Biotech offers an AI-powered diagnostic platform with two core products: MetriDx™ for endometriosis detection and staging, and HERAfem™ for cervical cancer diagnosis. Both products share the same AI learning engine but differ in their detection modalities—MetriDx uses molecular mRNA expression profiling via RT-qPCR while HERAfem uses optical and electrical spectroscopy. The platform integrates into existing clinical workflows and improves diagnostic accuracy with each analysis through machine learning.

Product and service3 records
1MetriDx™
CategoryWomen's Health Diagnostics - Endometriosis
Description

A non-invasive molecular test for endometriosis detection and staging that uses mRNA expression profiling via RT-qPCR enhanced by AI-powered algorithms. Achieves 80% sensitivity and 95% specificity, with results available in 3-5 days via lab processing after Pipelle sampling. Designed for OB-GYN clinics, fertility clinics, primary care, and reference labs to replace surgical diagnostic laparoscopy.

2HERAfem™
CategoryWomen's Health Diagnostics - Cervical Cancer
Description

A non-invasive, point-of-care cervical cancer diagnostic device that detects CIN1+ lesions using optical and electrical spectroscopy with on-device AI classification. Delivers same-visit results in approximately two minutes without biopsy or lab processing, achieving 90% sensitivity and 77% specificity. Designed for primary care, rural and underserved healthcare environments.

3Hera Biotech Platform
CategoryAI-Powered Diagnostic Platform
Description

An AI-powered diagnostic platform that powers both MetriDx and HERAfem products, collecting biological and physical tissue information and analyzing complexity using adaptive AI/ML models trained on 20 billion+ data points across four proprietary datasets. Designed for frontline care settings including OB-GYN, fertility clinics, and primary care.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Selected for 10th class of Cedars-Sinai Accelerator, receiving $100,000 funding, mentorship, networking, and investor exposure. Culminated in Demo Day at HLTH Event 2024 in Las Vegas.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

DotLab develops a blood-based biomarker test for endometriosis, directly competing with Hera's MetriDx in the non-invasive endometriosis diagnostic space and serving a similar OB-GYN and fertility clinic customer base.

TypeDirect peer
Description

UE LifeSciences (operating the MobileODT cervical screening brand) offers AI-enabled visual cervical cancer screening, directly competing with Hera's HERAfem in point-of-care cervical cancer detection with a similar emerging-market public health focus.

TypeEmerging player
Description

AOA Dx is an early-stage women's cancer diagnostics company developing AI-enabled liquid biopsy tests for ovarian cancer, with comparable focus on underserved women's health oncology indications and AI-driven biomarker interpretation.

TypeEmerging player
Description

Cytovale develops AI-enabled rapid diagnostics (notably IntelliSep for sepsis), sharing Hera's AI-powered platform approach to non-invasive diagnostics with similar point-of-care deployment ambitions and machine learning interpretation engines.

TypeEmerging player
Description

TruDiagnostic uses AI/ML on multi-omics data (epigenetic and methylation biomarkers) for health diagnostics, overlapping with Hera's bioinformatics and multi-omics data infrastructure in the broader AI diagnostics category.

TypeEmerging player
Description

iCAD applies AI to cancer detection and therapy planning (notably breast and cervical), sharing Hera's AI-imaging-and-biomarker diagnostic approach for women's cancers with an established commercial footprint.

TypeBroad incumbent
Description

Hologic is a global women's health diagnostics leader with strong cervical cancer screening (ThinPrep, Genius) and molecular diagnostics franchises, representing a likely strategic acquirer or major competitor for Hera's HERAfem and MetriDx products.

TypeBroad incumbent
Description

QIAGEN is a leading molecular diagnostics and sample-preparation company with broad RT-qPCR workflows that overlap with MetriDx's laboratory-based molecular diagnostic methodology and could serve as a reference lab distribution partner.

TypeBroad incumbent
Description

BD is a major diagnostics and medical device incumbent with women's health and molecular diagnostic franchises, overlapping with Hera's combined diagnostics-device offering and serving as a likely strategic partner or acquirer.

TypeBroad incumbent
Description

Roche Diagnostics is the global leader in molecular diagnostics and women's health (including HPV primary screening via cobas), representing both a competitive threat and a likely strategic acquirer for an AI-enabled endometriosis and cervical cancer diagnostic platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hera Biotech

Women's Health Diagnosticsherabiotech.com

Hera Biotech is a clinical-stage women's health biotech developing AI-powered, non-invasive diagnostics for endometriosis (MetriDx) and cervical cancer (HERAfem), targeting OB-GYN, fertility clinics, primary care, and public health systems across the US, Latin America, Asia, and Africa.

What Hera Biotech does

Hera Biotech is a clinical-stage biotechnology company developing non-invasive, tissue-based diagnostics for two under-served areas of women's health: endometriosis and cervical cancer. Its core products are MetriDx, a laboratory-developed molecular test that uses RT-qPCR mRNA expression profiling augmented by AI/ML algorithms to detect and stage endometriosis (reported at 80% sensitivity and 95% specificity), and HERAfem, a point-of-care cervical cancer diagnostic device that combines optical and electrical spectroscopy with on-device AI to detect CIN1+ lesions (reported at 90% sensitivity and 77% specificity). Both products run on a shared adaptive AI platform that improves with each diagnostic result and is trained on 20 billion+ data points across 1,000+ samples and four proprietary datasets.

The company targets OB-GYN clinics, fertility clinics, primary care settings, reference laboratories, and public health systems. Its revenue strategy is multi-modal: MetriDx operates under a Laboratory Developed Test (LDT) model with unique billing opportunities and potential of up to $4M annual revenue per average fertility clinic; HERAfem is positioned as a hardware device sale targeting Latin America (2026), Asia, and Africa (2027). The company is also pursuing reimbursement pathways that could reduce endometriosis diagnostic cost by approximately $17K per patient. Both products remain under development and have not yet received FDA or COFEPRIS approval.

Hera Biotech is a Delaware corporation headquartered in San Antonio, Texas, with regional operations in Monterrey, Mexico and Basel, Switzerland. It is led by CEO Somer Baburek (2 prior exits) and COO/CSO Cinzia Donato, PhD (multi-patent holder, formerly at Scailyte), and is venture-backed with approximately $2M in seed funding plus a $100K Cedars-Sinai Accelerator grant, while actively raising a Series A round for commercialization.

Hera Biotech firmographics

Firmographics
Name
Hera Biotech
Legal name
Hera Biotech, Inc.
Website
https://herabiotech.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Hera Biotech is a clinical-stage women's health biotech developing AI-powered, non-invasive diagnostics for endometriosis (MetriDx) and cervical cancer (HERAfem), targeting OB-GYN, fertility clinics, primary care, and public health systems across the US, Latin America, Asia, and Africa.
Ownership category
akta.pro rank

Hera Biotech industry classification

Industry
Product category
Women's Health Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Non-invasive diagnostics
  • Molecular diagnostic testing
  • AI-powered diagnostics
  • Women's health devices
  • Cervical cancer screening

Where Hera Biotech is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Hera Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. MetriDx™ Diagnostic Testing: Lab-developed test (LDT) model for endometriosis detection, generating revenue through laboratory testing fees prior to FDA approval. Proprietary components and workflow enable unique billing opportunities. Estimated potential of up to $4M annual revenue per average fertility clinic.
  2. HERAfem™ Device Sales: Point-of-care diagnostic device for cervical cancer screening. Revenue streams planned to turn on pre-COFEPRIS clearance in Latin America (2026) with expansion to Asia and Africa (2027). Device designed for wireless operation with data backup capabilities.
  3. Reimbursement and Billing: Proprietary diagnostic workflow with unique billing opportunities. MetriDx can cut diagnostic cost by approximately $17K per patient compared to traditional surgical pathway, with reimbursement pathways already in motion.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Hera Biotech product offering

Product offering

Core offering

Hera Biotech develops non-invasive, tissue-based AI-powered diagnostic products for women's health. Its core offerings are MetriDx™, a molecular test using mRNA expression profiling (RT-qPCR) for endometriosis detection and staging (80% sensitivity, 95% specificity), and HERAfem™, a point-of-care cervical cancer diagnostic device using optical and electrical spectroscopy (90% sensitivity, 77% specificity). Both products are powered by a shared adaptive AI/ML platform trained on over 20 billion data points.

Product overview

Hera Biotech offers an AI-powered diagnostic platform with two core products: MetriDx™ for endometriosis detection and staging, and HERAfem™ for cervical cancer diagnosis. Both products share the same AI learning engine but differ in their detection modalities—MetriDx uses molecular mRNA expression profiling via RT-qPCR while HERAfem uses optical and electrical spectroscopy. The platform integrates into existing clinical workflows and improves diagnostic accuracy with each analysis through machine learning.

Differentiator

Problem solved

Functional benefit

Brands

  • MetriDx™: Non-invasive molecular test for endometriosis detection and staging using mRNA expression profiling via RT-qPCR with AI-powered algorithms. 80% sensitivity, 95% specificity. Targets to replace surgical diagnostic laparoscopy.
  • HERAfem™

Products and services

  • MetriDx™ A non-invasive molecular test for endometriosis detection and staging that uses mRNA expression profiling via RT-qPCR enhanced by AI-powered algorithms. Achieves 80% sensitivity and 95% specificity, with results available in 3-5 days via lab processing after Pipelle sampling. Designed for OB-GYN clinics, fertility clinics, primary care, and reference labs to replace surgical diagnostic laparoscopy.
  • HERAfem™ A non-invasive, point-of-care cervical cancer diagnostic device that detects CIN1+ lesions using optical and electrical spectroscopy with on-device AI classification. Delivers same-visit results in approximately two minutes without biopsy or lab processing, achieving 90% sensitivity and 77% specificity. Designed for primary care, rural and underserved healthcare environments.
  • Hera Biotech Platform An AI-powered diagnostic platform that powers both MetriDx and HERAfem products, collecting biological and physical tissue information and analyzing complexity using adaptive AI/ML models trained on 20 billion+ data points across four proprietary datasets. Designed for frontline care settings including OB-GYN, fertility clinics, and primary care.

Quantifiable outcome

  • MetriDx achieves 80% sensitivity and 95% specificity for endometriosis detection
  • +5 more outcomes

Companies that use Hera Biotech

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Hera Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Hera Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cedars-Sinai AcceleratorcoreStrategic or Co-development Partner · 1 August 2024Selected for 10th class of Cedars-Sinai Accelerator, receiving $100,000 funding, mentorship, networking, and investor exposure. Culminated in Demo Day at HLTH Event 2024 in Las Vegas.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Hera Biotech competitors and assessment

Company assessment

Direct peers

  • DotLab: DotLab develops a blood-based biomarker test for endometriosis, directly competing with Hera's MetriDx in the non-invasive endometriosis diagnostic space and serving a similar OB-GYN and fertility clinic customer base.
  • MobileODT (UE LifeSciences): UE LifeSciences (operating the MobileODT cervical screening brand) offers AI-enabled visual cervical cancer screening, directly competing with Hera's HERAfem in point-of-care cervical cancer detection with a similar emerging-market public health focus.

Emerging players

  • AOA Dx: AOA Dx is an early-stage women's cancer diagnostics company developing AI-enabled liquid biopsy tests for ovarian cancer, with comparable focus on underserved women's health oncology indications and AI-driven biomarker interpretation.
  • Cytovale: Cytovale develops AI-enabled rapid diagnostics (notably IntelliSep for sepsis), sharing Hera's AI-powered platform approach to non-invasive diagnostics with similar point-of-care deployment ambitions and machine learning interpretation engines.
  • TruDiagnostic: TruDiagnostic uses AI/ML on multi-omics data (epigenetic and methylation biomarkers) for health diagnostics, overlapping with Hera's bioinformatics and multi-omics data infrastructure in the broader AI diagnostics category.
  • iCAD: iCAD applies AI to cancer detection and therapy planning (notably breast and cervical), sharing Hera's AI-imaging-and-biomarker diagnostic approach for women's cancers with an established commercial footprint.

Broad incumbents

  • Hologic: Hologic is a global women's health diagnostics leader with strong cervical cancer screening (ThinPrep, Genius) and molecular diagnostics franchises, representing a likely strategic acquirer or major competitor for Hera's HERAfem and MetriDx products.
  • QIAGEN: QIAGEN is a leading molecular diagnostics and sample-preparation company with broad RT-qPCR workflows that overlap with MetriDx's laboratory-based molecular diagnostic methodology and could serve as a reference lab distribution partner.
  • Becton Dickinson (BD): BD is a major diagnostics and medical device incumbent with women's health and molecular diagnostic franchises, overlapping with Hera's combined diagnostics-device offering and serving as a likely strategic partner or acquirer.
  • F. Hoffmann-La Roche: Roche Diagnostics is the global leader in molecular diagnostics and women's health (including HPV primary screening via cobas), representing both a competitive threat and a likely strategic acquirer for an AI-enabled endometriosis and cervical cancer diagnostic platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights1 record

Customer concentration

Hera Biotech social profiles

Digital presence

Hera Biotech compliance and trust

Trust signal

Compliance3 records

Hera Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hera Biotech leadership team

Management profile

Number of profiles

Profiles10 records

Hera Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Hera Biotech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hera Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hera Biotech

What does Hera Biotech do?

Hera Biotech develops non-invasive, tissue-based AI-powered diagnostic products for women's health. Its core offerings are MetriDx™, a molecular test using mRNA expression profiling (RT-qPCR) for endometriosis detection and staging (80% sensitivity, 95% specificity), and HERAfem™, a point-of-care cervical cancer diagnostic device using optical and electrical spectroscopy (90% sensitivity, 77% specificity). Both products are powered by a shared adaptive AI/ML platform trained on over 20 billion data points.

Is Hera Biotech a public or private company?

Hera Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hera Biotech founded?

Hera Biotech was founded in 2022. It employs 11 to 50 people.

Where is Hera Biotech based?

Hera Biotech is headquartered in San Antonio, United States, in the North America region.

How does Hera Biotech make money?

Three revenue lines are on record. MetriDx™ Diagnostic Testing is the primary driver. The others are HERAfem™ Device Sales and reimbursement and Billing.

Who are Hera Biotech's main competitors?

Direct peers on record are DotLab and MobileODT (UE LifeSciences). Emerging players are AOA Dx, Cytovale, TruDiagnostic and iCAD. Broad incumbents are Hologic, QIAGEN, Becton Dickinson (BD) and F. Hoffmann-La Roche.

Does Hera Biotech have an API?

No public API is recorded for Hera Biotech.

What industry is Hera Biotech in?

Hera Biotech's product category is Women's Health Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesNo More Invasive Tests: Hera Biotech’s Endometriosis SolutionHera Biotech is developing a less invasive endometriosis diagnostic test, having raised $3 million in seed and bridge rounds. The company is seeking $5 million in Series A funding to finalize product development and launch its first diagnostic to market.TPRSan Antonio startup Hera Biotech developing non-invasive endometriosis diagnostic testsHera Biotech acquired Swiss company Scailyte to develop non-invasive endometriosis diagnostic tests. The Scailyte test is 78% sensitive and 91% specific, while Hera's original test is 97% sensitive and specific. The company aims for FDA clearance by 2026.Tech.euSwiss AI company Scailyte sells Endometriosis diagnostic assets to Hera BiotechSwiss AI company Scailyte agreed to sell its endometriosis diagnostic assets to US Hera Biotech. The deal, with undisclosed financials, consolidates the only two tissue-based endometriosis diagnostic programs. Hera plans to launch its first diagnostic product in the US fertility market in late 2024.YahooHera Biotech to Make First Acquisition in the Endometriosis Diagnostic Market and Enter Into Strategic Partnership With ScailyteHera Biotech agreed to acquire Scailyte's endometriosis diagnostic assets and IP, consolidating the two tissue-based diagnostic programs. The combined portfolio's first product will launch in the US fertility market in late 2024, with a second product for OB/GYN follow-up. The transaction is expected to close by end of January 2024.Business Wire BlogHera Biotech to Make First Acquisition in the Endometriosis Diagnostic Market and Enter Into Strategic Partnership With ScailyteHera Biotech agreed to acquire Scailyte's endometriosis diagnostic assets and IP, consolidating the two tissue-based diagnostic programs. The companies expect to close the deal by end of January 2024, with the first product launching in the US fertility market in late 2024. Hera also announced a $15M Series A raise.MondayAI enabled diagnostics in the femtech market. — Monday CapitalHera Biotech has developed a revolutionary approach to diagnosing endometriosis using their technology called MetriDx, which involves a minimally invasive biopsy and AI analysis of gene-level activity. This method offers more accurate diagnosis and potential insights for personalized treatment, significantly impacting the management of endometriosis. The ability to analyze gene expression related to the disease could enhance fertility treatments and improve patient outcomes.VC News DailyHera Biotech Announces $2M in Seed FundingHera Biotech has secured $2 million in seed funding to complete its second clinical trial. The company is currently raising a Series-A round to expand these trials and prepare for commercialization of its test. Additionally, Hera has established a scientific advisory board comprised of top researchers to support its development efforts.FinSMEsHera Biotech Closes $1.9M Seed FundingHera Biotech has closed a $1.9 million seed funding round led by Coyote Ventures, Stella Angels, Althea Group Ventures, and the Kendra Scott Women’s Entrepreneurial Leadership Institute. The startup intends to use these funds to complete an in-patient human clinical study for its MetriDx™ endometriosis diagnostic device and support its regulatory pathway with the US FDA.Business Wire BlogHera Biotech Closes Oversubscribed $1.9 Million Seed Raise For Novel Diagnostic Test for EndometriosisSan Antonio-based Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support the commercialization of its non-surgical diagnostic test for endometriosis, MetriDx™. The funds will be used to complete in-patient human clinical studies, expand the company's IP portfolio, and support a regulatory pathway with the US FDA. Investors in the round include Coyote Ventures, Stella Angels, Althea Group Ventures, and the Kendra Scott Women’s Entrepreneurial Leadership Institute.